LeafNLP Demos
Back to explore

Report #2888092

Received Mar 9, 2026

Reports are unverified and do not show that a vaccine caused an event. Full disclaimer

Overview

Sex
Male
Age
Age unknown
State
PA
Recovered
Unknown
Vaccinated
—
Onset
—
Days to onset
—
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
TDAPTDAP (BOOSTRIX)GLAXOSMITHKLINE BIOLOGICALSUNKUNKSYR

Symptoms (1)

Incorrect route of product administration

Symptom narrative

Intramuscular formulation administered by other route; This non-serious case was reported by a consumer via call center representative and described the occurrence of intramuscular formulation administered by other route in a male patient who received DTPa (Reduced antigen) (Boostrix) for prophylaxis. On an unknown date, the patient received Boostrix. On an unknown date, an unknown time after receiving Boostrix, the patient experienced intramuscular formulation administered by other route (Verbatim: Intramuscular formulation administered by other route). The outcome of the intramuscular formulation administered by other route was not applicable. Additional Information: GSK Receipt Date:27-FEB-2026 The Boostrix was administered to the patient intravenously rather than intramuscularly. The batch number was not provided and the request for the information has been made.